{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '61', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum', 'pregnancy test is required. In such cases, the participant must be excluded from', 'participation if the serum pregnancy result is positive.', 'Additional requirements for pregnancy testing during and after study intervention are', 'located in Appendix 2.', 'The investigator is responsible for review of medical history, menstrual history, and', 'recent sexual activity to decrease the risk for inclusion of a woman with an early', 'undetected pregnancy.', 'Informed Consent', '11. The participant (or legally acceptable representative if applicable) has provided', 'documented informed consent/assent for the study.', 'Additional Categories', '12. Have adequately controlled blood pressure (BP) with or without antihypertensive', 'medications, defined as BP <150/90 mm Hg and no change in antihypertensive', 'medications within 1 week prior to randomization.', '13. Have adequate organ function as defined in the following table (Table 1). Specimens', 'must be collected within 10 days before the start of study intervention.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '62', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Table 1', 'Adequate Organ Function Laboratory Values', 'System', 'Laboratory Value', 'Hematological', 'ANC', '1500/L', 'Platelets', '>100,000/uL', 'Hemoglobin', '9.0g/dL or >5.6 mmol/La', 'Renal', 'Creatinine or', '<1.5 X ULN or', 'Measured or calculated CrCl', '>30 mL/min for participant with creatinine', '(GFR can also be used in place of creatinine or', 'levels >1.5 X institutional ULN', 'CrCl)', 'Hepatic', 'Total bilirubin', '<1.5 X ULN or direct bilirubin >ULN for', 'participants with total bilirubin levels', '>1.5 X ULN', 'AST (SGOT) and ALT (SGPT)', '2.5 X ULN (<5 X ULN for participants with', 'liver metastases)', 'Coagulation', 'INR or PT', '<1.5 X ULN unless participant is receiving', 'aPTT/PTT', 'anticoagulant therapy as long as INR/PT or', 'aPTT/PTT is within therapeutic range of', 'intended use of anticoagulants', 'Abbreviations: ALT (SGPT) = alanine aminotransferase (serum glutamic pyruvic transaminase);', 'ANC = absolute neutrophil count; aPTT = activated partial thromboplastin time; AST (SGOT) = aspartate', 'aminotransferase (serum glutamic oxaloacetic transaminase); CrCl = creatinine clearance; GFR = glomerular', 'filtration rate; INR = international normalized ratio; PT = prothrombin time; ULN = upper limit of normal.', 'Note: This table includes eligibility-defining laboratory value requirements for treatment; laboratory value', 'requirements should be adapted according to local regulations and guidelines for the administration of specific', 'chemotherapies.', 'a', 'Criteria must be met without erythropoietin dependency and without packed red blood cell transfusion', 'within last 2 weeks.', 'b', 'CrCl should be calculated per institutional standard.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '63', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '5.2', 'Exclusion Criteria', 'The participant must be excluded from the study if the participant:', 'Medical Conditions', '1. Has known untreated central nervous system metastases and/or carcinomatous', 'meningitis. Participants with previously treated brain metastases may participate provided', 'they are radiologically stable ie, without evidence of progression for at least 4 weeks by', 'repeat imaging (note: repeat imaging should be performed during study screening),', 'clinically stable, and without requirement of steroid treatment for at least 14 days before', 'first dose of study intervention.', '2. Has clinically significant hemoptysis (at least 0.5 teaspoon of bright red blood) or tumor', 'bleeding within 2 weeks before the first dose of study intervention.', '3. Has radiographic evidence of encasement or invasion of a major blood vessel, or of', 'intratumoral cavitation.', 'NOTE:', 'The degree of proximity to major blood vessels should be considered because of', 'the potential risk of severe hemorrhage associated with tumor shrinkage/necrosis', 'following lenvatinib therapy.', 'In the chest, major blood vessels include the main pulmonary artery, the left and', 'right pulmonary arteries, the 4 major pulmonary veins, the superior or inferior', 'vena cava, and the aorta.', '4. Has a known history of an additional malignancy, except if the participant has undergone', 'potentially curative therapy with no evidence of that disease recurrence for at least', '3 years since initiation of that therapy.', 'Note: The time requirement for no evidence of disease for at least 3 years does not apply', 'to the NSCLC for which a participant is enrolled in the study. The time requirement also', 'does not apply to participants who underwent successful definitive resection of basal cell', 'carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in', 'situ cervical cancer, or other in situ cancers.', '5. Has an active autoimmune disease that has required systemic treatment in the past 2 years', '(ie, with the use of disease-modifying agents, corticosteroids, or immunosuppressive', 'drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid', 'replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form', 'of systemic treatment and is allowed.', '6. Has had an allogeneic tissue/solid organ transplant.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}